Sun Bio­Phar­ma founder Michael Cullen steps up; Se­maThera set­tles on per­ma­nent CEO; On­coSec nabs Kel­lie Mal­loy Fo­ert­er from Sy­neos

→ David Kay­sen is step­ping down from Sun Bio­Phar­ma af­ter three years in the pres­i­dent and CEO of­fice, hand­ing the reins to ex­ec­u­tive chair­man and founder Michael Cullen. His de­par­ture is noth­ing against him, the com­pa­ny notes, but a re­sult of “the need for cost re­duc­tions to fo­cus fur­ther spend­ing on the cur­rent Phase 1a/1b clin­i­cal tri­al in the front-line com­bi­na­tion study of SBP-101 with gem­c­itabine and nab-pa­cli­tax­el for the treat­ment of metasta­t­ic pan­cre­at­ic can­cer.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER